Among the different radioimmune schedules tested, the initial administration of an anti-CD25 (interleukin-2 receptor alpha chain), followed by concurrent treatment with RT (40 Gy in five fractions of 8 Gy per fraction) and an anti-CD137- (component of tumor necrosis factor receptor family) (Figure 2e) achieved the most promising result, with 70% of complete responses after 60 days from tumor inoculation [30]. The gene discussed is IL2RA; the disease is neoplasm.